DKSH has signed a strategic agreement with NanoFCM to promote their NanoAnalyzer range of analytical instruments in key Asian markets. This partnership is in line with the strategic focus of DKSH Business Unit Technology to solidify its position as a leading integrated solutions provider for the scientific Instrumentation market.
Media release
Switzerland, February 1, 2021 – DKSH Business Unit Technology has entered into an exclusive partnership with NanoFCM, an innovative manufacturer of a nano flow cytometer platform, headquartered in Fujian, China. DKSH will provide marketing, sales, distribution and after-sales services support in selected markets across Asia, including Singapore, Taiwan and Thailand.
NanoFCM has developed the NanoAnalyzer that now enables true flow-cytometry measurement at the sub-micron scale, and down to particle sizes unreachable by any other flow cytometers. Flow NanoAnalyzer is a powerful tool for life sciences, nanoscience and nanotechnology studies. It can be used for the biomolecular characterization of extracellular vesicles, viruses, nanomedicine and nanomaterials.
“DKSH has in-depth knowledge and a broad network of laboratories doing research on biomolecules and nanoparticles. We are convinced that DKSH is the right partner to help us grow in key Asian markets, especially by introducing our new technology to the extracellular vesicle research community for the development of new cancer therapies,” said Dimitri Aubert, VP Sales & Marketing, NanoFCM.
Marco Farina, Senior Director, Business Development, Scientific Instrumentation, commented: “The partnership with NanoFCM helps strengthen our leadership in biomolecular characterization and expand our life sciences footprint. We are confident to grow the market with NanoCFM, leveraging our knowledge through our Center of Excellence, good sales coverage, strong application support and world class after sales services.”
For further information, please contact:
DKSH Business Unit Technology
Irene Chen
Director, Group Marketing
Phone +886 2 8752 7611
irene.yr.chen@dksh.com
About NanoFCM
Implementing strategies for single-molecule fluorescence detection in a sheathed flow, NanoFCM provides a versatile and powerful platform —— NanoAnalyzer for the multiparameter analysis of functional nanoparticles (7-1000 nm) at the single-particle level. By precise quantification of the ultraweak elastically scattered light from single nanoparticles, high-resolution size distribution comparable to that of electron microscopy can be acquired in 1-2 minutes. Biochemical properties of single nanoparticles can be analyzed via concurrent multi-color fluorescence detection. The NanoAnalyzer is therefore expected to become a powerful tool for life science, nanoscience and nanotechnology studies. The NanoAnalyzer has been sold to the top research institutions and high-tech enterprises at home and abroad. It has established a large number of high-end user cases, and has a very good market prospects. MD Anderson Cancer Center, Exosomics, NIH, Imperial College London, Sydney University, Taiwan University and other leading global research institutions and high-tech companies are our customers.
About DKSH
DKSH is the leading Market Expansion Services provider with a focus on Asia. The Group helps companies to grow across the Business Units Healthcare, Consumer Goods, Performance Materials and Technology. The service portfolio covers sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales services. Publicly listed on the SIX Swiss Exchange, the Group operates in 36 markets with 33,350 specialists, generating net sales of CHF 11.6 billion in 2019. With its Swiss heritage, DKSH has been deeply rooted in Asia Pacific since 1865. The DKSH Business Unit Technology offers complete solutions for specialized industrial applications. With around 1,670 specialists, the Business Unit generated net sales of CHF 431.9 million in 2019.